Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adarsh Joshi

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Contemporary Clinical Trials|May 20, 2017
Statistical design for a confirmatory trial with a continuous predictive biomarker: A case studyAdarsh Joshi, Jenny Zhang, Liang Fang
Journal of the American Statistical Association|August 6, 2009
Log-Linear Models for Gene AssociationJianhua Hu, Adarsh Joshi, Valen E Johnson
European Journal of Cancer (Oxford, England : 1990)|June 18, 2015
A randomised non-comparative phase II trial of cixutumumab (IMC-A12) or ramucirumab (IMC-1121B) plus mitoxantrone and prednisone in men with metastatic docetaxel-pretreated castration-resistant prostate cancerMaha Hussain, Dana Rathkopf, Glenn Liu, et al.
Cancer|March 1, 2014
A phase 2, single-arm study of ramucirumab in patients with metastatic renal cell carcinoma with disease progression on or intolerance to tyrosine kinase inhibitor therapyJorge A Garcia, Gary R Hudes, Toni K Choueiri, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 30, 2014
A phase II, open-label study of ramucirumab in combination with paclitaxel and carboplatin as first-line therapy in patients with stage IIIB/IV non-small-cell lung cancerD Ross Camidge, Eamon M Berge, Robert C Doebele, et al.
Plos One|November 19, 2013
Tumor cell expression of vascular endothelial growth factor receptor 2 is an adverse prognostic factor in patients with squamous cell carcinoma of the lungTimothy R Holzer, Angie D Fulford, Drew M Nedderman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 4, 2013
A phase II and biomarker study of ramucirumab, a human monoclonal antibody targeting the VEGF receptor-2, as first-line monotherapy in patients with advanced hepatocellular cancerAndrew X Zhu, Richard S Finn, Mary Mulcahy, et al.
Gynecologic Oncology|July 15, 2014
A phase II study of ramucirumab (IMC-1121B) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinomaRichard T Penson, Kathleen M Moore, Gini F Fleming, et al.
Journal of Hepatology|November 7, 2017
Safety, efficacy and pharmacodynamics of vesatolimod (GS-9620) in virally suppressed patients with chronic hepatitis BHarry L A Janssen, Maurizia R Brunetto, Yoon Jun Kim, et al.
Antiviral Therapy|July 16, 2020
Safety, pharmacokinetics and pharmacodynamics of selgantolimod, an oral Toll-like receptor 8 agonist: a Phase Ia study in healthy subjectsMaribel Reyes, Justin D Lutz, Audrey H Lau, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Contemporary Clinical Trials|May 20, 2017
Statistical design for a confirmatory trial with a continuous predictive biomarker: A case studyAdarsh Joshi, Jenny Zhang, Liang Fang
Journal of the American Statistical Association|August 6, 2009
Log-Linear Models for Gene AssociationJianhua Hu, Adarsh Joshi, Valen E Johnson
European Journal of Cancer (Oxford, England : 1990)|June 18, 2015
A randomised non-comparative phase II trial of cixutumumab (IMC-A12) or ramucirumab (IMC-1121B) plus mitoxantrone and prednisone in men with metastatic docetaxel-pretreated castration-resistant prostate cancerMaha Hussain, Dana Rathkopf, Glenn Liu, et al.
Cancer|March 1, 2014
A phase 2, single-arm study of ramucirumab in patients with metastatic renal cell carcinoma with disease progression on or intolerance to tyrosine kinase inhibitor therapyJorge A Garcia, Gary R Hudes, Toni K Choueiri, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 30, 2014
A phase II, open-label study of ramucirumab in combination with paclitaxel and carboplatin as first-line therapy in patients with stage IIIB/IV non-small-cell lung cancerD Ross Camidge, Eamon M Berge, Robert C Doebele, et al.
Plos One|November 19, 2013
Tumor cell expression of vascular endothelial growth factor receptor 2 is an adverse prognostic factor in patients with squamous cell carcinoma of the lungTimothy R Holzer, Angie D Fulford, Drew M Nedderman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 4, 2013
A phase II and biomarker study of ramucirumab, a human monoclonal antibody targeting the VEGF receptor-2, as first-line monotherapy in patients with advanced hepatocellular cancerAndrew X Zhu, Richard S Finn, Mary Mulcahy, et al.
Gynecologic Oncology|July 15, 2014
A phase II study of ramucirumab (IMC-1121B) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinomaRichard T Penson, Kathleen M Moore, Gini F Fleming, et al.
Journal of Hepatology|November 7, 2017
Safety, efficacy and pharmacodynamics of vesatolimod (GS-9620) in virally suppressed patients with chronic hepatitis BHarry L A Janssen, Maurizia R Brunetto, Yoon Jun Kim, et al.
Antiviral Therapy|July 16, 2020
Safety, pharmacokinetics and pharmacodynamics of selgantolimod, an oral Toll-like receptor 8 agonist: a Phase Ia study in healthy subjectsMaribel Reyes, Justin D Lutz, Audrey H Lau, et al.
Pageof 2